{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:13:54Z","timestamp":1776532434855,"version":"3.51.2"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006134","name":"Foundation for Promotion of Material Science and Technology of Japan","doi-asserted-by":"publisher","award":["JP19K18836"],"award-info":[{"award-number":["JP19K18836"]}],"id":[{"id":"10.13039\/501100006134","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00417-024-06499-6","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T07:02:25Z","timestamp":1715238145000},"page":"3191-3200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy"],"prefix":"10.1007","volume":"262","author":[{"given":"Yoko","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohdai","family":"Kitamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-0797","authenticated-orcid":false,"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"6499_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H et al (2019) Pachychoroid disease. Eye 33:14\u201333. https:\/\/doi.org\/10.1038\/s41433-018-0158-4","journal-title":"Eye"},{"key":"6499_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1097\/IAE.0b013e3182953df4","volume":"33","author":"DJ Warrow","year":"2013","unstructured":"Warrow DJ, Hoang QV, Freund KB (2013) Pachychoroid pigment epitheliopathy. Retina 33:1659\u20131672. https:\/\/doi.org\/10.1097\/IAE.0b013e3182953df4","journal-title":"Retina"},{"key":"6499_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1\u20139. https:\/\/doi.org\/10.1097\/IAE.0000000000000331","journal-title":"Retina"},{"key":"6499_CR4","doi-asserted-by":"publisher","first-page":"e0212055","DOI":"10.1371\/journal.pone.0212055","volume":"14","author":"K Azuma","year":"2019","unstructured":"Azuma K, Tan X, Asano S et al (2019) The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. PLoS One 14:e0212055. https:\/\/doi.org\/10.1371\/journal.pone.0212055","journal-title":"PLoS One"},{"key":"6499_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10384-018-0562-0","volume":"62","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Hiroe T, Morimoto M et al (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144\u2013150. https:\/\/doi.org\/10.1007\/s10384-018-0562-0","journal-title":"Jpn J Ophthalmol"},{"key":"6499_CR6","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.2147\/OPTH.S334641","volume":"15","author":"T Kinoshita","year":"2021","unstructured":"Kinoshita T, Mori J, Hatanaka A et al (2021) Visual outcome and treatment frequency of Anti-VEGF therapy using the treat-and-extend and treatment cessation regimen for exudative age-related macular degeneration and pachychoroid neovasculopathy. Clin Ophthalmol 15:4405\u20134418. https:\/\/doi.org\/10.2147\/OPTH.S334641","journal-title":"Clin Ophthalmol"},{"key":"6499_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","volume":"3","author":"M Hata","year":"2019","unstructured":"Hata M, Tagawa M, Oishi A et al (2019) Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol Retina 3:1016\u20131025. https:\/\/doi.org\/10.1016\/j.oret.2019.06.013","journal-title":"Ophthalmol Retina"},{"key":"6499_CR8","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1038\/s41598-020-65346-w","volume":"10","author":"K Azuma","year":"2020","unstructured":"Azuma K, Okubo A, Nomura Y et al (2020) Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci Rep 10:8337. https:\/\/doi.org\/10.1038\/s41598-020-65346-w","journal-title":"Sci Rep"},{"key":"6499_CR9","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/jcm10102168","volume":"10","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Mori R, Wakatsuki Y et al (2021) Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med 10:2168. https:\/\/doi.org\/10.3390\/jcm10102168","journal-title":"J Clin Med"},{"key":"6499_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1038\/s41433-019-0511-2","volume":"33","author":"R Sacconi","year":"2019","unstructured":"Sacconi R, Tomasso L, Corbelli E et al (2019) Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. Eye 33:1809\u20131817. https:\/\/doi.org\/10.1038\/s41433-019-0511-2","journal-title":"Eye"},{"key":"6499_CR11","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi T, Kubo N, Yamauchi M (2021) One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye 35:3367\u20133375. https:\/\/doi.org\/10.1038\/s41433-021-01418-z","journal-title":"Eye"},{"key":"6499_CR12","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.3390\/jcm11154614","volume":"11","author":"K Yamashiro","year":"2022","unstructured":"Yamashiro K, Yanagi Y, Koizumi H et al (2022) Relationship between pachychoroid and polypoidal choroidal vasculopathy. J Clin Med 11:4614. https:\/\/doi.org\/10.3390\/jcm11154614","journal-title":"J Clin Med"},{"key":"6499_CR13","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4103\/ijo.IJO_1481_18","volume":"67","author":"R Roy","year":"2019","unstructured":"Roy R, Saurabh K, Shah D, Goel S (2019) Treatment outcomes of pachychoroid neovasculopathy with photodynamic therapy and anti-vascular endothelial growth factor. Indian J Ophthalmol 67:1678\u20131683. https:\/\/doi.org\/10.4103\/ijo.IJO_1481_18","journal-title":"Indian J Ophthalmol"},{"key":"6499_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10384-020-00722-7","volume":"64","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Mukai R, Kikuchi Y et al (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203\u2013209. https:\/\/doi.org\/10.1007\/s10384-020-00722-7","journal-title":"Jpn J Ophthalmol"},{"key":"6499_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima Y, Maruyama-Inoue M, Ito A et al (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279\u20131285. https:\/\/doi.org\/10.1007\/s00417-020-04661-4","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6499_CR16","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s10792-020-01522-1","volume":"40","author":"F Sartini","year":"2020","unstructured":"Sartini F, Figus M, Casini G et al (2020) Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options. Int Ophthalmol 40:3577\u20133589. https:\/\/doi.org\/10.1007\/s10792-020-01522-1","journal-title":"Int Ophthalmol"},{"key":"6499_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s10792-021-01754-9","volume":"41","author":"B Karasu","year":"2021","unstructured":"Karasu B, Celebi ARC (2021) An efficacy comparison of combination of different anti-vascular endothelial growth factors and photodynamic therapy in patients with pachychoroid neovasculopathy. Int Ophthalmol 41:1989\u20132000. https:\/\/doi.org\/10.1007\/s10792-021-01754-9","journal-title":"Int Ophthalmol"},{"key":"6499_CR18","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki A, Kusuhara S, Otsuji T et al (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One 16:e0248760. https:\/\/doi.org\/10.1371\/journal.pone.0248760","journal-title":"PLoS One"},{"key":"6499_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/ph15040483","volume":"15","author":"M Sato-Akushichi","year":"2022","unstructured":"Sato-Akushichi M, Ono S, Taneda T et al (2022) One-year outcome of combination therapy with full or reduced photodynamic therapy and one anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Pharm Basel Switz 15:483. https:\/\/doi.org\/10.3390\/ph15040483","journal-title":"Pharm Basel Switz"},{"key":"6499_CR20","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1007\/s00417-023-06030-3","volume":"261","author":"J Takeuchi","year":"2023","unstructured":"Takeuchi J, Ota H, Nakano Y et al (2023) Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 261:2235\u20132243. https:\/\/doi.org\/10.1007\/s00417-023-06030-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6499_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003841","author":"T Hikichi","year":"2023","unstructured":"Hikichi T, Kubo N, Tabata M, Kurabe H (2023) Enlargement of choroidal neovascularization before recurrence after photodynamic therapy for pachychoroid neovasculopathy. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000003841","journal-title":"Retina"},{"key":"6499_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06387-z","author":"N Tanaka","year":"2024","unstructured":"Tanaka N, Azuma K, Aoki S et al (2024) Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-024-06387-z","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6499_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1167\/iovs.16-20967","volume":"58","author":"M Hata","year":"2017","unstructured":"Hata M, Yamashiro K, Ooto S et al (2017) intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 58:292\u2013298. https:\/\/doi.org\/10.1167\/iovs.16-20967","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6499_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4103\/2211-5056.362040","volume":"12","author":"JB Park","year":"2022","unstructured":"Park JB, Kim K, Kang MS et al (2022) Central serous chorioretinopathy: Treatment. Taiwan J Ophthalmol 12:394\u2013408. https:\/\/doi.org\/10.4103\/2211-5056.362040","journal-title":"Taiwan J Ophthalmol"},{"key":"6499_CR25","doi-asserted-by":"publisher","first-page":"16248","DOI":"10.1038\/s41598-020-73303-w","volume":"10","author":"M Tagawa","year":"2020","unstructured":"Tagawa M, Ooto S, Yamashiro K et al (2020) Characteristics of pachychoroid neovasculopathy. Sci Rep 10:16248. https:\/\/doi.org\/10.1038\/s41598-020-73303-w","journal-title":"Sci Rep"},{"key":"6499_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2147\/OPTH.S285257","volume":"15","author":"S Elfandi","year":"2021","unstructured":"Elfandi S, Ooto S, Miyata M et al (2021) Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: Comparison with typical neovascular age-related macular degeneration. Clin Ophthalmol 15:1539\u20131549. https:\/\/doi.org\/10.2147\/OPTH.S285257","journal-title":"Clin Ophthalmol"},{"key":"6499_CR27","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.1038\/s41598-021-87340-6","volume":"11","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Oguchi Y, Omori T et al (2021) Changes in complement activation products after anti-VEGF injection for choroidal neovascularization in age-related macular degeneration and pachychoroid disease. Sci Rep 11:8464. https:\/\/doi.org\/10.1038\/s41598-021-87340-6","journal-title":"Sci Rep"},{"key":"6499_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IAE.0000000000001689","volume":"38","author":"RF Spaide","year":"2018","unstructured":"Spaide RF (2018) Disease expression in nonexudative age-related macular degeneration varies with choroidal thickness. Retina 38:708\u2013716. https:\/\/doi.org\/10.1097\/IAE.0000000000001689","journal-title":"Retina"},{"key":"6499_CR29","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1097\/IAE.0b013e3182680a66","volume":"32","author":"AT Fung","year":"2012","unstructured":"Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829\u20131837. https:\/\/doi.org\/10.1097\/IAE.0b013e3182680a66","journal-title":"Retina"},{"key":"6499_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.ajo.2015.08.028","volume":"160","author":"KK Dansingani","year":"2015","unstructured":"Dansingani KK, Balaratnasingam C, Klufas MA et al (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243-1254.e2. https:\/\/doi.org\/10.1016\/j.ajo.2015.08.028","journal-title":"Am J Ophthalmol"},{"key":"6499_CR31","doi-asserted-by":"publisher","first-page":"16204","DOI":"10.1038\/srep16204","volume":"5","author":"M Miyake","year":"2015","unstructured":"Miyake M, Ooto S, Yamashiro K et al (2015) Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204. https:\/\/doi.org\/10.1038\/srep16204","journal-title":"Sci Rep"},{"key":"6499_CR32","first-page":"198","volume":"119","author":"NM Bressler","year":"1960","unstructured":"Bressler NM (1960) Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol Chic Ill 119:198\u2013207","journal-title":"Arch Ophthalmol Chic Ill"},{"key":"6499_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10384-014-0333-5","volume":"58","author":"Y Nomura","year":"2014","unstructured":"Nomura Y, Takahashi H, Tan X et al (2014) Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration. Jpn J Ophthalmol 58:443\u2013447. https:\/\/doi.org\/10.1007\/s10384-014-0333-5","journal-title":"Jpn J Ophthalmol"},{"key":"6499_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/bjophthalmol-2021-318782","volume":"106","author":"BK Betzler","year":"2022","unstructured":"Betzler BK, Ding J, Wei X et al (2022) Choroidal vascularity index: a step towards software as a medical device. Br J Ophthalmol 106:149\u2013155. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-318782","journal-title":"Br J Ophthalmol"},{"key":"6499_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"6499_CR36","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1097\/IAE.0000000000001040","volume":"36","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Chhablani J, Tan K-A et al (2016) Choroidal vascularity index in central serous chorioretinopathy. Retina 36:1646\u20131651. https:\/\/doi.org\/10.1097\/IAE.0000000000001040","journal-title":"Retina"},{"key":"6499_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ajo.2015.09.032","volume":"161","author":"Y Kuroda","year":"2016","unstructured":"Kuroda Y, Yamashiro K, Tsujikawa A et al (2016) Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol 161:94-103.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.09.032","journal-title":"Am J Ophthalmol"},{"key":"6499_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s0039-6257(05)80092-x","volume":"39","author":"AC Bird","year":"1995","unstructured":"Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367\u2013374. https:\/\/doi.org\/10.1016\/s0039-6257(05)80092-x","journal-title":"Surv Ophthalmol"},{"key":"6499_CR39","first-page":"671","volume":"119","author":"K Takahashi","year":"2015","unstructured":"Takahashi K, Shiraga F, Ishida S et al (2015) Diagnostic criteria for atrophic age-related macular degeneration. Nippon Ganka Gakkai Zasshi 119:671\u2013677","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"6499_CR40","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Guymer R, Mon\u00e9s JM et al (2020) Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: Systematic literature review and expert opinion. Ophthalmology 127:648\u2013659. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.010","journal-title":"Ophthalmology"},{"key":"6499_CR41","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung BJ, Kim JY, Lee JH et al (2019) Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy. Sci Rep 9:2055. https:\/\/doi.org\/10.1038\/s41598-019-38504-y","journal-title":"Sci Rep"},{"key":"6499_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/jop.2018.0107","volume":"35","author":"HJ Cho","year":"2019","unstructured":"Cho HJ, Jung SH, Cho S et al (2019) Intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther 35:174\u2013181. https:\/\/doi.org\/10.1089\/jop.2018.0107","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"6499_CR43","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.18240\/ijo.2016.07.16","volume":"9","author":"Y Tong","year":"2016","unstructured":"Tong Y, Zhao K-K, Feng D et al (2016) Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review. Int J Ophthalmol 9:1028\u20131037. https:\/\/doi.org\/10.18240\/ijo.2016.07.16","journal-title":"Int J Ophthalmol"},{"key":"6499_CR44","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1097\/IAE.0b013e31822bf6b1","volume":"31","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y et al (2011) One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 31:1921\u20131927. https:\/\/doi.org\/10.1097\/IAE.0b013e31822bf6b1","journal-title":"Retina"},{"key":"6499_CR45","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00417-019-04426-8","volume":"257","author":"W Park","year":"2019","unstructured":"Park W, Kim M, Kim RY, Park Y-H (2019) Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol 257:2155\u20132161. https:\/\/doi.org\/10.1007\/s00417-019-04426-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6499_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0000000000000809","volume":"36","author":"JH Lee","year":"2016","unstructured":"Lee JH, Lee WK (2016) One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina 36:889\u2013895. https:\/\/doi.org\/10.1097\/IAE.0000000000000809","journal-title":"Retina"},{"key":"6499_CR47","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/bjo.87.12.1453","volume":"87","author":"W-M Chan","year":"2003","unstructured":"Chan W-M, Lam DSC, Lai TYY et al (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453\u20131458. https:\/\/doi.org\/10.1136\/bjo.87.12.1453","journal-title":"Br J Ophthalmol"},{"key":"6499_CR48","first-page":"835","volume":"120","author":"U Schmidt-Erfurth","year":"1960","unstructured":"Schmidt-Erfurth U, Laqua H, Schl\u00f6tzer-Schrehard U et al (1960) (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol Chic Ill 120:835\u2013844","journal-title":"Arch Ophthalmol Chic Ill"},{"key":"6499_CR49","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K et al (2020) Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol 138:935\u2013942. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2443","journal-title":"JAMA Ophthalmol"},{"key":"6499_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10384-016-0479-4","volume":"61","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Sugiyama A et al (2017) Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab. Jpn J Ophthalmol 61:61\u201366. https:\/\/doi.org\/10.1007\/s10384-016-0479-4","journal-title":"Jpn J Ophthalmol"},{"key":"6499_CR51","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S386222","volume":"17","author":"T Miyakubo","year":"2023","unstructured":"Miyakubo T, Mukai R, Matsumoto H et al (2023) Comparison of the 2-year results of photodynamic therapy with aflibercept and aflibercept monotherapy for polypoidal choroidal vasculopathy. Clin Ophthalmol 17:571\u2013577. https:\/\/doi.org\/10.2147\/OPTH.S386222","journal-title":"Clin Ophthalmol"},{"key":"6499_CR52","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00417-020-04959-3","volume":"259","author":"TJ van Rijssen","year":"2021","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P et al (2021) Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. Graefes Arch Clin Exp Ophthalmol 259:905\u2013910. https:\/\/doi.org\/10.1007\/s00417-020-04959-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6499_CR53","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41433-022-02067-6","volume":"37","author":"K Kawai","year":"2023","unstructured":"Kawai K, Miyata M, Ooto S et al (2023) Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy. Eye 37:1067\u20131072. https:\/\/doi.org\/10.1038\/s41433-022-02067-6","journal-title":"Eye"},{"key":"6499_CR54","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00417-020-04940-0","volume":"259","author":"V Castro-Navarro","year":"2021","unstructured":"Castro-Navarro V, Behar-Cohen F, Chang W et al (2021) Pachychoroid: current concepts on clinical features and pathogenesis. Graefes Arch Clin Exp Ophthalmol 259:1385\u20131400. https:\/\/doi.org\/10.1007\/s00417-020-04940-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06499-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06499-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T03:38:44Z","timestamp":1728358724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06499-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6499"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06499-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the research ethics committee of the Graduate School of Medicine and Faculty of Medicine at the University of Tokyo (#2217).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the the Graduate School of Medicine and Faculty of Medicine at the University of Tokyo\u00a0and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was given for patient information to be stored in the hospital database and used for research. Otherwise, based on the regulations of the Japanese Guidelines for Epidemiologic Study 2021, the study protocols did not require that each patient provide written informed consent. Instead, the protocol was posted at the outpatient clinic and\/or website of the department to notify study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Ryo Obata received honoraria for speaking\/consulting from Santen, Bayer, Novartis, Chugai, Senju and Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}